Cited by 322Bipolar Disorder and TreatmentPersonality Disorders and PsychopathologyTreatment of Major Depression

Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder: Findings From the STEP-BD

Open access
Goldberg, Joseph F., Perlis, Roy H., Bowden, Charles L., Thase, Michael E., Miklowitz, David J., Marangell, Lauren B., Calabrese, Joseph R., Nierenberg, Andrew A. +1 more·2009·American Journal of Psychiatry

Abstract

OBJECTIVE: Little is known about how often bipolar depressive episodes are accompanied by subsyndromal manic symptoms in bipolar I and II disorders. The authors sought to determine the frequency and clinical correlates of manic symptoms during episodes of bipolar depression. METHOD: From among 4,107 enrollees in the National Institute of Mental Health's Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 1,380 individuals met criteria for bipolar I or II depressive syndromes at the time of enrollment and were assessed for concomitant manic symptoms. Illness characteristics were compared in patients with pure bipolar depressed episodes and those with mixed depressive presentations. RESULTS: Two-thirds of the subjects with bipolar depressed episodes had concomitant manic symptoms, most often distractibility, flight of ideas or racing thoughts, and psychomotor agitation. Patients with any mixed features were significantly more likely than those with pure bipolar depressed episodes to have early age at illness onset, rapid cycling in the past year, bipolar I subtype, history of suicide attempts, and more days in the preceding year with irritability or mood elevation. CONCLUSIONS: Manic symptoms often accompany bipolar depressive episodes but may easily be overlooked when they appear less prominent than depressive features. Subsyndromal manic symptoms during bipolar I or II depression demarcate a more common, severe, and psychopathologically complex clinical state than pure bipolar depression and merit recognition as a distinct nosologic entity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2008.08050746

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Goldberg, J. F., Perlis, R. H., Bowden, C. L., Thase, M. E., Miklowitz, D. J., Marangell, L. B., Calabrese, J. R., Nierenberg, A. A., & Sachs, G. S.
Affiliations
Icahn School of Medicine at Mount Sinai (US)
Venue
American Journal of Psychiatry
Published
2009-02
Volume
166
Issue
2
Pages
173-181
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2136900530
Cited by
322
References
41
Citations by year
2026: 8 · 2025: 14 · 2024: 2 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 18 · 2019: 19 · 2018: 12 · 2017: 25 · 2016: 32 · 2015: 24 · 2014: 25 · 2013: 20 · 2012: 35
FWCI
18.50
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Defense
  • American Psychiatric Publishing
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Jazz Pharmaceuticals
  • Supernus Pharmaceuticals
  • Dainippon Sumitomo Pharma
  • Servier
  • National Institutes of Health (n01mh80001-12-0-0, 1k23mh001936-01a1)
  • National Institute of Mental Health (K23 MH-01936, N01-MH80001, N01 MH080001)
  • UCB Pharma
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
bipolar depression, mixed features, bipolar I disorder, bipolar II disorder, distractibility, flight of ideas, psychomotor agitation, rapid cycling, age of onset, suicide attempts, irritability, mood improvement, disease classification
MeSH terms
Adult, Affect, Antidepressive Agents, Bipolar Disorder, Cross-Sectional Studies, Major Depressive Disorder, Diagnosis, Differential, Euphoria, Female, Humans, Irritable Mood, Longitudinal Studies, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics, Treatment Outcome, Antimanic Agents, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review